These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 29802542)

  • 1. Influence of Antigen Mass on the Pharmacokinetics of Therapeutic Antibodies in Humans.
    Ternant D; Azzopardi N; Raoul W; Bejan-Angoulvant T; Paintaud G
    Clin Pharmacokinet; 2019 Feb; 58(2):169-187. PubMed ID: 29802542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Target-mediated drug disposition model for drugs that bind to more than one target.
    Gibiansky L; Gibiansky E
    J Pharmacokinet Pharmacodyn; 2010 Aug; 37(4):323-46. PubMed ID: 20669044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic Variability of Therapeutic Antibodies in Humans: A Comprehensive Review of Population Pharmacokinetic Modeling Publications.
    Bensalem A; Ternant D
    Clin Pharmacokinet; 2020 Jul; 59(7):857-874. PubMed ID: 32170579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacokinetic variability of therapeutic antibodies].
    Ternant D; Chhun S
    Med Sci (Paris); 2019 Dec; 35(12):1130-1136. PubMed ID: 31903927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modelling of the Time-Varying Pharmacokinetics of Therapeutic Monoclonal Antibodies: A Literature Review.
    Petitcollin A; Bensalem A; Verdier MC; Tron C; Lemaitre F; Paintaud G; Bellissant E; Ternant D
    Clin Pharmacokinet; 2020 Jan; 59(1):37-49. PubMed ID: 31452150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacokinetics of therapeutic monoclonal antibodies.
    Keizer RJ; Huitema AD; Schellens JH; Beijnen JH
    Clin Pharmacokinet; 2010 Aug; 49(8):493-507. PubMed ID: 20608753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physiologically-based modeling to predict the clinical behavior of monoclonal antibodies directed against lymphocyte antigens.
    Glassman PM; Balthasar JP
    MAbs; 2017; 9(2):297-306. PubMed ID: 27892793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies.
    Glassman PM; Balthasar JP
    J Pharmacokinet Pharmacodyn; 2016 Aug; 43(4):427-46. PubMed ID: 27377311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis.
    Ternant D; Bejan-Angoulvant T; Passot C; Mulleman D; Paintaud G
    Clin Pharmacokinet; 2015 Nov; 54(11):1107-23. PubMed ID: 26123705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development.
    Mould DR; Green B
    BioDrugs; 2010 Feb; 24(1):23-39. PubMed ID: 20055530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins.
    Ternant D; Paintaud G
    Expert Opin Biol Ther; 2005 Sep; 5 Suppl 1():S37-47. PubMed ID: 16187939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic drug monitoring of monoclonal antibodies: Applicability based on their pharmacokinetic properties.
    Imamura CK
    Drug Metab Pharmacokinet; 2019 Feb; 34(1):14-18. PubMed ID: 30606646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The pharmacokinetics of monoclonal antibodies].
    Keizer RJ; Huitema AD; Damen CW; Schellens JH; Beijnen JH
    Ned Tijdschr Geneeskd; 2007 Mar; 151(12):683-8. PubMed ID: 17447593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gaining insights into the consequences of target-mediated drug disposition of monoclonal antibodies using quasi-steady-state approximations.
    Grimm HP
    J Pharmacokinet Pharmacodyn; 2009 Oct; 36(5):407-20. PubMed ID: 19728050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Target-mediated drug disposition model for drugs with two binding sites that bind to a target with one binding site.
    Gibiansky L; Gibiansky E
    J Pharmacokinet Pharmacodyn; 2017 Oct; 44(5):463-475. PubMed ID: 28725976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T65 antigen modulation in a phase I monoclonal antibody trial with chronic lymphocytic leukemia patients.
    Schroff RW; Farrell MM; Klein RA; Oldham RK; Foon KA
    J Immunol; 1984 Sep; 133(3):1641-8. PubMed ID: 6379051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
    Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
    Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
    Weisman MH; Moreland LW; Furst DE; Weinblatt ME; Keystone EC; Paulus HE; Teoh LS; Velagapudi RB; Noertersheuser PA; Granneman GR; Fischkoff SA; Chartash EK
    Clin Ther; 2003 Jun; 25(6):1700-21. PubMed ID: 12860493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biodistribution and histological localization of anti-human colon cancer monoclonal antibody (MAb) 1A3: the influence of administered MAb dose on tumor uptake.
    Fenwick JR; Philpott GW; Connett JM
    Int J Cancer; 1989 Dec; 44(6):1017-27. PubMed ID: 2691405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of antigen-dependent clearance on pharmacokinetics of anti-heparin-binding EGF-like growth factor (HB-EGF) monoclonal antibody.
    Kasai N; Yoshikawa Y; Enokizono J
    MAbs; 2014; 6(5):1220-8. PubMed ID: 25517307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.